$69.5 M

OCX Mkt cap, 04-Dec-2018
OncoCyte Net income (Q2, 2018)-8.3 M
OncoCyte EBIT (Q2, 2018)-8.1 M
OncoCyte Cash, 30-Jun-201810.3 M

OncoCyte Income Statement

Annual

USDFY, 2016FY, 2017

Sales and marketing expense

2.4m

R&D expense

5.7m7.2m

General and administrative expense

5.5m9.2m

Operating expense total

11.1m18.8m

EBIT

(11.1m)(18.8m)

Interest expense

28.0k217.0k

Net Income

(11.2m)(19.4m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Sales and marketing expense

655.0k477.0k710.0k658.0k1.2m

R&D expense

1.7m1.2m1.4m1.8m2.0m1.8m1.5m3.8m

General and administrative expense

1.2m1.3m1.2m2.0m1.1m4.3m1.8m3.1m

Operating expense total

2.9m(2.5m)(2.6m)4.5m(3.6m)(6.8m)3.9m8.1m

EBIT

(2.9m)(2.5m)(2.6m)(4.5m)(3.6m)(6.8m)(3.9m)(8.1m)

Interest expense

4.0k11.0k13.0k13.0k65.0k71.0k60.0k117.0k

Interest income

4.0k11.0k13.0k

Net Income

(2.9m)(2.5m)(2.6m)(4.7m)(3.8m)(6.9m)(3.8m)(8.3m)

OncoCyte Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

10.2m7.6m

Accounts Receivable

14.3m

Inventories

285.0k

Current Assets

12.7m8.5m

Total Assets

14.4m10.2m

Accounts Payable

422.0k175.0k

Current Liabilities

4.3m4.5m

Total Liabilities

4.6m5.8m

Retained Earnings

(35.3m)(54.7m)

Total Equity

9.9m4.4m

Financial Leverage

1.5 x2.3 x

OncoCyte Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(11.2m)(19.4m)

Depreciation and Amortization

145.0k338.0k

Inventories

101.0k

Accounts Payable

(48.0k)

Cash From Operating Activities

(7.5m)(13.4m)

Purchases of PP&E

(106.0k)(91.0k)

Cash From Investing Activities

(181.0k)843.0k

Cash From Financing Activities

9.9m10.0m

Interest Paid

130.0k

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9m)(2.5m)(2.6m)(4.7m)

Accounts Payable

403.0k192.0k870.0k211.0k

OncoCyte Ratios

USDY, 2018

Financial Leverage

1.8 x
Report incorrect company information

OncoCyte Operating Metrics

FY, 2016

Patents Issued

1

Patents and Patent Applications

13
Report incorrect company information